Countries covered: Iran
Iran has a large and predominantly young population, which should be instrumental in driving the expansion of the pharmaceutical market over the coming years. BMI expects the value of the drug market to reach US$1.93bn by 2010. Drug prices, which are still among the lowest in the region, are rising as domestic companies seek to boost revenue. Domestic output accounted for around 90% of the country's requirements in 2005.
Government support for privatisation should also help the drug market improve, whilst making local manufacturers more efficient. All state-owned companies that import medicines are required to be privatised and terminate their activities by March 2007. In the past, all drug imports came through four state-owned companies, with local distribution undertaken by six government firms. At present, foreign drugmakers can import drugs through local offices, although the government still greatly favours local producers. All drug imports have to be approved by the Ministry of Health (MoH).
BMI's adjusted Business Environment Rankings for the Middle East & Africa reveal that Iran is in 12th place, ahead only of Nigeria and Zimbabwe. This is primarily due to political and economic uncertainty in the country, coupled with poor intellectual property standards. However, Iran's market is experiencing robust growth, although the dominant position of local manufacturing provides a substantial obstacle to investment.
Iranian drug exports are growing, led by demand from close regional neighbours. Two markets that are increasing in importance are Iraq and Afghanistan as these countries' economies begin to slowly recover from the effects of war. Afghanistan is currently Iran's largest drug export partner. Local player Iran Pharmaceutical Development and Investment Company IPDC) has yet to see sales return to pre-war levels. Future export growth will concentrate on the former Soviet sates in Central Asia, and the potentially lucrative African market. Meanwhile, Oman and Iran are planning to increase their co-operation in the field of healthcare, which could see a rise in exports from Iran to Oman.
Key Benefits of Report
Rely On Our Independent 5-Year Forecasts As A Benchmark
to test other views - a key input for successful budgetary and strategic business planning.
Target Business Opportunities & Risks
hrough our reviews of latest industry trends, regulatory changes, and major deals, projects and investments
Exploit Latest Competitive Intelligence & Company SWOTS
on your competitors and peers through company rankings by sales, market share and ownership structure - includes multinational and national companies.
Additional Information
Scope of Report
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end-2010 for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
Generics market (US$bn)/ as % of total market
Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.Related Reports:
Snapshots Poland Pharmaceuticals 2009
Snapshots Hungary Pharmaceuticals 2009
Snapshots Venezuela Pharmaceuticals 2009
Snapshots Spain Pharmaceuticals 2009
Snapshots US Pharmaceuticals 2009
Snapshots South Africa Pharmaceuticals 2009
Nigeria Pharmaceuticals and Healthcare Report Q1 2010
Australia Pharmaceuticals and Healthcare Report Q1 2010
Thailand Pharmaceuticals and Healthcare Report Q1 2010
Poland Pharmaceuticals and Healthcare Report Q1 2010
|
(0 items)
